AP3268A - Co-crystals and salts of CCR3-inhibitors - Google Patents
Co-crystals and salts of CCR3-inhibitorsInfo
- Publication number
- AP3268A AP3268A AP2013006679A AP2013006679A AP3268A AP 3268 A AP3268 A AP 3268A AP 2013006679 A AP2013006679 A AP 2013006679A AP 2013006679 A AP2013006679 A AP 2013006679A AP 3268 A AP3268 A AP 3268A
- Authority
- AP
- ARIPO
- Prior art keywords
- ccr3
- crystals
- inhibitors
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186901 | 2010-10-07 | ||
| PCT/EP2011/067437 WO2012045803A1 (en) | 2010-10-07 | 2011-10-06 | Co-crystals and salts of ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2013006679A0 AP2013006679A0 (en) | 2013-01-31 |
| AP3268A true AP3268A (en) | 2015-05-31 |
Family
ID=44741339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2013006679A AP3268A (en) | 2010-10-07 | 2011-10-06 | Co-crystals and salts of CCR3-inhibitors |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US8742115B2 (es) |
| EP (1) | EP2625174B1 (es) |
| JP (1) | JP5794713B2 (es) |
| KR (3) | KR102163874B1 (es) |
| CN (1) | CN103140486B (es) |
| AP (1) | AP3268A (es) |
| AR (1) | AR083353A1 (es) |
| AU (1) | AU2011311530B2 (es) |
| BR (2) | BR112013008211B1 (es) |
| CA (1) | CA2807255C (es) |
| CL (1) | CL2013000488A1 (es) |
| CO (1) | CO6710910A2 (es) |
| CY (1) | CY1116168T1 (es) |
| DK (1) | DK2625174T3 (es) |
| EA (1) | EA029097B1 (es) |
| EC (1) | ECSP13012600A (es) |
| ES (1) | ES2535264T3 (es) |
| GE (1) | GEP20166488B (es) |
| HR (1) | HRP20150419T1 (es) |
| HU (1) | HUE024540T2 (es) |
| IL (1) | IL224269A (es) |
| MA (1) | MA34545B1 (es) |
| ME (1) | ME02040B (es) |
| MX (1) | MX2013003785A (es) |
| MY (1) | MY167898A (es) |
| NZ (1) | NZ605827A (es) |
| PE (1) | PE20140188A1 (es) |
| PL (1) | PL2625174T3 (es) |
| PT (1) | PT2625174E (es) |
| RS (1) | RS53858B1 (es) |
| SG (1) | SG188949A1 (es) |
| SI (1) | SI2625174T1 (es) |
| TW (1) | TWI546294B (es) |
| UA (1) | UA109290C2 (es) |
| UY (1) | UY33655A (es) |
| WO (1) | WO2012045803A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) * | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| BR112019020430A2 (pt) | 2017-04-05 | 2021-03-30 | Alkahest, Inc. | Métodos e composições para tratar doença associada à retina usando inibidores de ccr3 |
| MX2019011988A (es) * | 2017-04-05 | 2020-01-20 | Alkahest Inc | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3. |
| US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
| JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
| US11426399B2 (en) | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| CA3111433A1 (en) * | 2018-09-26 | 2020-04-02 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| JP2023529719A (ja) * | 2020-06-11 | 2023-07-11 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患の転帰改善方法 |
| US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116313A2 (en) * | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| CA2318088A1 (en) | 1998-01-21 | 1999-07-29 | Yoshisuke Nakasato | Chemokine receptor antagonists and methods of use therefor |
| CA2319781A1 (en) | 1998-02-02 | 1999-08-05 | Liping Wang | Cyclic amine modulators of chemokine receptor activity |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1448528A2 (en) | 2001-11-29 | 2004-08-25 | Schering Corporation | Preparation of pharmaceutical salts of 4((z)-(4-bromophenyl)(ethoxyimino)methyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-4'-methyl-1,4'bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
| WO2004064762A2 (en) | 2003-01-21 | 2004-08-05 | S.S.C.I. Inc. | Novel cocrystallization |
| SG131946A1 (en) | 2003-10-24 | 2007-05-28 | Hoffmann La Roche | Ccr3 receptor antagonists |
| JP2007520556A (ja) | 2004-02-05 | 2007-07-26 | シェーリング コーポレイション | Ｃｃｒ３アンタゴニストとして有用なピペリジン誘導体 |
| US7803786B2 (en) * | 2004-06-17 | 2010-09-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| ES2348122T3 (es) | 2006-04-20 | 2010-11-30 | F. Hoffmann-La Roche Ag | Derivados de diazepano moduladores de receptores de quimioquina. |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2011
- 2011-06-10 UA UAA201305572A patent/UA109290C2/ru unknown
- 2011-10-06 AP AP2013006679A patent/AP3268A/xx active
- 2011-10-06 GE GEAP201113082A patent/GEP20166488B/en unknown
- 2011-10-06 DK DK11764572.1T patent/DK2625174T3/da active
- 2011-10-06 PE PE2013000781A patent/PE20140188A1/es not_active Application Discontinuation
- 2011-10-06 MX MX2013003785A patent/MX2013003785A/es active IP Right Grant
- 2011-10-06 MA MA35770A patent/MA34545B1/fr unknown
- 2011-10-06 UY UY0001033655A patent/UY33655A/es unknown
- 2011-10-06 PL PL11764572T patent/PL2625174T3/pl unknown
- 2011-10-06 RS RS20150131A patent/RS53858B1/en unknown
- 2011-10-06 SI SI201130394T patent/SI2625174T1/sl unknown
- 2011-10-06 HU HUE11764572A patent/HUE024540T2/hu unknown
- 2011-10-06 ME MEP-2015-17A patent/ME02040B/me unknown
- 2011-10-06 CA CA2807255A patent/CA2807255C/en active Active
- 2011-10-06 TW TW100136338A patent/TWI546294B/zh active
- 2011-10-06 PT PT11764572T patent/PT2625174E/pt unknown
- 2011-10-06 US US13/267,417 patent/US8742115B2/en active Active
- 2011-10-06 MY MYPI2013000801A patent/MY167898A/en unknown
- 2011-10-06 CN CN201180047995.1A patent/CN103140486B/zh active Active
- 2011-10-06 KR KR1020177037823A patent/KR102163874B1/ko active IP Right Grant
- 2011-10-06 ES ES11764572.1T patent/ES2535264T3/es active Active
- 2011-10-06 AR ARP110103717A patent/AR083353A1/es unknown
- 2011-10-06 SG SG2013013305A patent/SG188949A1/en unknown
- 2011-10-06 AU AU2011311530A patent/AU2011311530B2/en active Active
- 2011-10-06 BR BR112013008211-9A patent/BR112013008211B1/pt active IP Right Grant
- 2011-10-06 BR BR122021010665-7A patent/BR122021010665B1/pt active IP Right Grant
- 2011-10-06 WO PCT/EP2011/067437 patent/WO2012045803A1/en active Application Filing
- 2011-10-06 NZ NZ605827A patent/NZ605827A/en unknown
- 2011-10-06 EP EP11764572.1A patent/EP2625174B1/en active Active
- 2011-10-06 EA EA201300436A patent/EA029097B1/ru unknown
- 2011-10-06 KR KR1020137008683A patent/KR101844215B1/ko active IP Right Grant
- 2011-10-06 KR KR1020197025850A patent/KR102239690B1/ko active IP Right Grant
- 2011-10-06 JP JP2013532190A patent/JP5794713B2/ja active Active
-
2013
- 2013-01-17 IL IL224269A patent/IL224269A/en unknown
- 2013-02-19 CL CL2013000488A patent/CL2013000488A1/es unknown
- 2013-04-08 CO CO13090552A patent/CO6710910A2/es unknown
- 2013-05-03 EC ECSP13012600 patent/ECSP13012600A/es unknown
-
2014
- 2014-01-22 US US14/160,646 patent/US20140135307A1/en not_active Abandoned
- 2014-12-17 US US14/572,889 patent/US9233950B2/en active Active
-
2015
- 2015-04-07 CY CY20151100331T patent/CY1116168T1/el unknown
- 2015-04-15 HR HRP20150419TT patent/HRP20150419T1/hr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116313A2 (en) * | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
Non-Patent Citations (1)
| Title |
|---|
| TING P C ET AL: "The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 5, 1 March 2005 (2005-03-01), pages 1375-1378, XP025314524 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3268A (en) | Co-crystals and salts of CCR3-inhibitors | |
| IL226489A0 (en) | Salts and crystalline forms of a substance | |
| ZA201308851B (en) | Storage of respiratory produce | |
| IL226477A (en) | Salts and polymorphic forms of Aptinib | |
| HK1178149A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4--- | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| HK1183014A1 (en) | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- | |
| EP2772483A4 (en) | 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| EP2548859A4 (en) | PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
| EP2702034A4 (en) | PREPARATION OF FINGOLIMOD AND ITS SALTS | |
| HK1207643A1 (en) | Amides of 2-amino-4-arylthiazole compounds and their salts 2--4- | |
| EP2581369A4 (en) | METHOD OF MANUFACTURING DRONEDARON AND ITS SALTS | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| EP2601178A4 (en) | SALTS OF LAPATINIB | |
| ZA201207945B (en) | Salts of dexlansoprazole and their preparation | |
| RS55226B1 (sr) | Kokristali ciprodinila | |
| HU1000688D0 (en) | Use of trifluoro-phal | |
| GB201010704D0 (en) | Storage of respiratory produce | |
| GB201004359D0 (en) | Storage of respiratory produce | |
| GB201011957D0 (en) | Co-crystals | |
| GB201011958D0 (en) | Co-crystals | |
| GB201005627D0 (en) | Co-crystals |